The inferior vena cava hanging maneuver for hepatocellular carcinoma with right atrial tumor thrombus

Chang, Yi-Lin; Lin, Kuo‐Hua; Lee, Kwong-Chiu; Chen, Yao‐Li

doi:10.1016/j.asjsur.2020.01.006

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the prognosis of RA tumor thrombi is poor, and the identification of safe and effective local therapies is required. Local therapies include surgical resection ( 4 ), microwave ablation, transarterial chemoembolization, and radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, in China, hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths (accounting 326,000 deaths), with 370,000 new cases in 2015 ( 2 ). HCC with a tumor thrombus extending into the inferior vena cava (IVC) or the right atrium (RA) is rare, accounting for 3.8% of the HCC cases ( 3 , 4 ). In addition, vasculature invasion is a poor prognostic factor in patients with HCC ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus

Qian

Gong

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe treatment of hepatocellular carcinoma (HCC) with right atrium (RA) and inferior vena cava (IVC) tumor thrombi is challenging, with the standard treatment being not well established. Immunotherapy plus antiangiogenic therapy is a potentially effective treatment for patients with advanced HCC. Here, we described the case of a patient with HCC with RA and IVC tumor thrombi who achieved a successful response from radiotherapy and targeted therapy plus immunotherapy.Case SummaryA 62-year-old women presented with severe bilateral lower extremity edema identified as recurrent HCC with RA and IVC tumor thrombi based on past medical history and computed tomography. The patient received palliative radiotherapy plus pembrolizumab and lenvatinib treatment and was relieved of disease symptoms of bilateral lower extremity edema. The HCC with RA and IVC tumor thrombi shrunk, and the progression-free survival of this patient was > seven months.ConclusionTumor thrombus-directed radiotherapy plus concurrent immunotherapy and targeted therapy might be a feasible and safe approach for patients with HCC with RA and IVC tumor thrombi.

show abstract

Section: Discussionmentioning

confidence: 99%